Experimental Drug Doubles One-Year Survival in Pancreatic Cancer

Experimental drug doubles one-year survival in pancreatic cancer

A new drug that works by making tumors more susceptible to chemotherapy and the immune system has increased survival in those with advanced pancreatic cancer in a trial.

A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment

Revolution Medicines announced a stunning survival benefit for its experimental drug in a Phase 3 pancreatic cancer study this week.  Patients with advanced pancreatic adenocarcinoma who were treated with the company’s daily pill called daraxonrasib lived a median of 13.2 months compared to 6.7 months for patients who received standard chemotherapy.  Revolution said it plans to use the data to apply for Food and Drug Administration approval, alt…

Revolution Medicines pancreatic cancer survival benefit details

Revolution Medicines’ Phase 3 pancreatic cancer result Revolution Medicines announced Phase 3 data for an experimental targeted treatment in advanced pancreatic cancer, reporting a large survival benefit compared with chemotherapy. The STAT+ coverage frames the finding as potentially ushering in a…

Daraxonrasib doubles survival in metastatic pancreatic cancer trial

Most people with previously-treated metastatic pancreatic cancer lived for at least one year after receiving the oral therapy candidate daraxonrasib in a clinical trial — a result that daraxonrasib’s developer Revolution Medicines described as an “unprecedented overall survival benefit” in this hard-to-treat cancer. Median survival among participants given daraxonrasib was approximtely double that of patients treated with standard chemotherapy, …